Cited by 225

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, Albert, Davis, Alan K, Erowid, Fire, Erowid, Earth, Griffiths, Roland R, Johnson, Matthew W·2019·Journal of Psychopharmacology

DOI 10.1177/0269881119845793

Open this paper in CoChat — free account

Abstract

Background: Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims: To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods: An anonymous online survey of individuals with prior AUD reporting cessation or reduction in alcohol use following psychedelic use in non-clinical settings. Results: 343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting retrospective criteria for severe AUD. Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption. After the psychedelic experience 83% no longer met AUD criteria. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced alcohol misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress. Conclusions: Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.

Integrity signals

Registry

Crossref · 10.1177/0269881119845793

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption‐II
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 2×
“This instrument consists of the first three items of the AUDIT (Saunders et al., 1993), and provides a validated measure of alcohol use, with AUDIT-C scores ⩾3 (in women) or ⩾4 (in men) indicating potential misuse (Bush et al., 1998).”
Method
Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“…depression (Carhart-Harris et al., 2016, 2017; dos Santos et al., 2016; Palhano-Fontes et al., 2019), as well as patients with symptoms of anxiety or depression associated with life-threatening illness (Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016).”
BackgroundSelf-citation
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 2×
“%) in the study sample was high, consistent with data showing significant comorbidity between AUD and mood and anxiety disorders (Grant et al., 2015; Hasin et al., 2018; Lai et al., 2015).”
Result
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citation
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 9×
“…found that both greater overall intensity of drug effects and greater mystical-type effects were highly correlated with subsequent decreases in percentage drinking days and percentage heavy drinking days, decreased craving, and increased alcohol abstinence self-efficacy (Bogenschutz et al., 2015).”
BackgroundInfluential
Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis
Lai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.031 · Cited by 941
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“…2008; Spitzer et al., 1996; Vollenweider et al., 1997), including a reemergence of clinical research examining psychedelics as potential treatments for addiction (Bogenschutz et al., 2015; Garcia-Romeu et al., 2015, 2016; Johnson et al., 2014, 2017a; Sessa and Johnson, 2015; Tupper et al., 2015).”
BackgroundSelf-citation
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Self-citation
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citation
Unhealthy Alcohol Use
Saitz, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042262 · Cited by 599
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 1×
“Email: mwj@jhu.edu research with LSD for alcohol misuse were not always consistent due to considerable variation in methods between studies (Abuzzahab and Anderson, 1971; Carhart-Harris et al., 2018; Hartogsohn, 2016, 2017; Johnson et al., 2008; Rucker et al., 2018).”
The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-3-201308060-00652 · Cited by 426
Behavioral counseling after screening for alcohol misuse in primary care: A systematic review and meta-analysis for the U.S. Preventive Services Task Force
Jonas, D. E., Garbutt, J. C., Amick, H. R., Brown, J. M., Brownley, K. A., Council, C. L., Viera, A. J., Wilkins, T. M., Schwartz, C. J., Richmond, E. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00544 · Cited by 387
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 1×
“…of AUD (WHO, 2018), and the limitations of current treatments, psychedelic-assisted treatment of AUD constitutes an innovative, timely, and compelling direction for future research for which safety and feasibility have been established (Bogenschutz et al., 2015; Johnson et al., 2008, 2018).”
BackgroundSelf-citation
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
Induction of innate immune genes in brain create the neurobiology of addiction
Crews, F. T., Zou, J., & Qin, L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.003 · Cited by 313
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227
The experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142
Self-citation
The epidemiology of 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140
Self-citation
Peyote in the Treatment of Alcoholism Among American Indians
ALBAUGH, B. J., & ANDERSON, P. O. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.11.1247 · Cited by 128
Use of d-Lysergic Acid Diethylamide in the Treatment of Alcoholism
Chwelos, N., Blewett, D. B., Smith, C. M., & Hoffer, A. (1959) · Quarterly Journal of Studies on Alcohol · doi:10.15288/qjsa.1959.20.577 · Cited by 111 · cited 2×
“…studied for their potential to help reduce problematic alcohol use in the 1950s through 1970s (Abuzzahab and Anderson, 1971; Bowen et al., 1970; Chwelos et al., 1959; Dyck, 2006; Hollister et al., 1969; Krebs and Johansen, 2012; Kurland et al., 1967; Ludwig et al., 1969; Mangini, 1998; Osmond…”
Background
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.08.009 · Cited by 104
Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice.
Oliveira-Lima, A. J., Santos, R., Hollais, A. W., Gerardi-Junior, C. A., Baldaia, M. A., Wuo-Silva, R., Yokoyama, T. S., Costa, J. L., Malpezzi-Marinho, E. L. A., Ribeiro-Barbosa, P. C., et al. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.01.032 · Cited by 91

Research works printed but not linked: 103

10.1159/000468273 · DOI
American Psychiatric Association, 1994, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
10.1176/appi.books.9780890425596 · DOI · Paper page
10.1001/jama.295.17.2003 · DOI · Paper page
10.3389/fpsyt.2018.00136 · DOI
10.1002/dta.1383 · DOI · Paper page
10.1300/J160v07n04_02 · DOI
10.1002/dta.1376 · DOI
10.1111/j.1530-0277.1995.tb01554.x · DOI
10.1007/s00213-017-4777-4 · DOI
10.1097/00005053-197002000-00003 · DOI
10.1111/j.1530-0277.2007.00403.x · DOI
10.1001/archinte.158.16.1789 · DOI · Paper page
10.1093/alcalc/agh156 · DOI
10.1111/j.1360-0443.2004.00763.x · DOI
10.15288/jsa.1993.54.297 · DOI
10.3389/fphar.2018.00561 · DOI
Center for Behavioral Health Statistics and Quality, 2017, 2016 National Survey on Drug Use and Health: Detailed Tables
10.1111/add.13477 · DOI
10.1016/B978-0-12-801284-0.00001-4 · DOI
10.1016/j.drugalcdep.2018.03.044 · DOI
10.1111/j.1360-0443.2004.00964.x · DOI · Paper page
Doblin R, 1991, J Transpers Psychol, 23, 1
10.1016/j.jep.2007.04.012 · DOI
10.1590/1516-4446-2015-1701 · DOI
10.1046/j.1360-0443.2002.00252.x · DOI
10.1093/shm/hkl039 · DOI
10.2174/1874473708666150107121331 · DOI · Paper page
10.1097/NMD.0000000000000113 · DOI · Paper page
Godinho AF, 2017, Electr J Biol, 13, 159
10.1097/00008877-199811000-00011 · DOI
10.1177/0269881108094300 · DOI · Paper page
Halpern JH, 2008, Med Sci Monit, 14, SR15
10.1177/0269881114565653 · DOI
10.1016/0006-3223(92)90059-9 · DOI
10.1055/s-2007-979352 · DOI · Paper page
10.17730/humo.49.3.m70273175tn234r1 · DOI
10.1176/ajp.125.10.1352 · DOI
10.5213/inj.1632604.302 · DOI
10.1016/0010-440X(93)90061-8 · DOI
IBM Corporation, 2016, IBM SPSS Statistics for Windows
10.1177/0269881116684335 · DOI
10.1177/0269881108093587 · DOI · Paper page
Johnston LD, O’Malley PM, Bachman JG, et al. (2016) Monitoring the Future National Survey Results on Drug Use, 1975–2015: Volume II, College Students and Adults Ages. Ann Arbor: MI: Institute for Social Research, pp. 19–55.
10.1111/j.1530-0277.2011.01523.x · DOI · Paper page
10.1111/j.1530-0277.2010.01362.x · DOI
10.1016/j.pnpbp.2015.06.008 · DOI · Paper page
10.1016/j.biopsych.2012.04.005 · DOI · Paper page
10.1016/j.biopsych.2014.04.010 · DOI · Paper page
10.1176/ajp.123.10.1202 · DOI
Lattin D, 2012, Distilled Spirits: Getting High, Then Sober, with a Famous Writer, a Forgotten Philosopher, and a Hopeless Drunk, 10.1525/9780520352629 · DOI
10.1176/ajp.126.1.59 · DOI
10.1177/0269881111420188 · DOI · Paper page
10.1111/j.1468-5906.2012.01685.x · DOI · Paper page
10.1111/j.1360-0443.2012.04054.x · DOI · Paper page
10.1177/0269881114568040 · DOI
10.1080/02791072.1998.10399714 · DOI
10.1177/070674371205700604 · DOI
10.1046/j.1360-0443.1998.9379793.x · DOI
10.1002/jclp.20000 · DOI
Miller WR, 2001, Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives
10.15288/jsa.2001.62.211 · DOI · Paper page
Moyer VA, 2013, Ann Int Med, 159, 210
10.1038/tp.2017.54 · DOI
Muthén LK, 1998, Mplus User’s Guide: Statistical Analysis with Latent Variables
10.1002/cpt.557 · DOI
10.3389/fphar.2018.00132 · DOI
10.1038/nrn3530 · DOI
Osmond H, 1967, The Use of LSD in Psychotherapy and Alcoholism, 434
10.2190/PM.38.4.a · DOI
10.1080/15313204.2013.843138 · DOI
10.1111/j.1530-0277.2002.tb02534.x · DOI · Paper page
10.3389/fphar.2017.00974 · DOI · Paper page
Ross S, 2012, Psychiatr Clin, 35, 357
10.1177/0269881116675512 · DOI · Paper page
10.1016/0306-4603(94)00072-7 · DOI
10.1111/acer.13522 · DOI
10.1111/j.1465-3362.2010.00217.x · DOI · Paper page
10.1001/archpsyc.1973.01750360040005 · DOI · Paper page
10.1007/s00213-017-4733-3 · DOI · Paper page
10.1002/cpt.776 · DOI
10.1016/j.neuropharm.2017.11.004 · DOI
10.1192/bjp.bp.114.148031 · DOI
Smart RG, 1966, Quart J Stud Alcohol, 27, 469, 10.15288/qjsa.1966.27.469 · DOI
Smith CM, 1958, Quart J Stud Alcohol, 19, 406, 10.15288/qjsa.1958.19.406 · DOI
Smith CM, 1959, Quart J Stud Alcohol, 20, 292, 10.15288/qjsa.1959.20.292 · DOI
10.1016/0006-3223(95)00418-1 · DOI
10.5888/pcd11.130293 · DOI
10.1001/archpsyc.1994.03950020009001 · DOI
10.1001/archpsyc.1994.03950020022002 · DOI · Paper page
10.1007/s00213-017-4754-y · DOI
Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2015, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide
10.1002/hbm.22562 · DOI
Tomsovic M, 1970, Quart J Stud Alcohol, 31, 932, 10.15288/qjsa.1970.31.932 · DOI
10.1503/cmaj.141124 · DOI · Paper page
10.1007/s00213-018-4988-3 · DOI · Paper page
10.1046/j.1360-0443.2003.00422.x · DOI · Paper page
10.1111/ejn.13572 · DOI
10.1093/alcalc/agl016 · DOI · Paper page
10.1016/S0893-133X(96)00246-1 · DOI · Paper page
10.15288/jsad.2008.69.878 · DOI
10.1177/0269881113513852 · DOI
World Health Organization (WHO), 2018, Management of Substance Abuse Unit: Global Status Report on Alcohol and Health, 2018

Sorted by citations

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citation
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541
Self-citation
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Self-citation
Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232

See all 225

Authors: Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W.
Affiliations: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Erowid Center, Grass Valley, CA, USA
ORCID: Garcia-Romeu, Albert
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2019-05-14
Volume: 33
Issue: 9
Pages: 1088-1101
ISSN: 0269-8811
1461-7285
DOI: 10.1177/0269881119845793
Cited by: 225
References: 42
Language: en
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Funders: national institute on drug abuse (T32DA07209, R01DA003889)
heffter research institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks